This suggests that a subgroup of CRIPTO-expressing HCC patients may benefit from a combinatorial treatment scheme and that sorafenib resistance may be circumventable by inhibition of GRP78 [96]. This evidence concerns the gene CRIPTO and hepatocellular carcinoma.